Update on the sexual impact of treatment for benign prostatic hyperplasia

Current Urology Reports

Volumn 13, Issue 6, 2012, Pages 433-440

  Bell, John Roger ^a   Laborde, Eric ^a  

^a OCHSNER CLINIC FOUNDATION   (United States)

Author keywords

5 alpha reductase inhibitor; Acute urinary retention; Alpha 1 adrenergic agonist; Anticholinergic; Benign prostatic hyperplasia; Erectile dysfunction; Holmium laser enucleation; Lower urinary tract symptoms; Phosphodiesterase inhibitor; Prostate photovaporization; Retrograde ejaculation; Simple prostatectomy; Transurethral resection of the prostate; UroLift

Indexed keywords

ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; DUTASTERIDE; FINASTERIDE; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; SILDENAFIL; SILODOSIN; TADALAFIL; TAMSULOSIN; TERAZOSIN; TESTOSTERONE; VARDENAFIL; STEROID 5ALPHA REDUCTASE INHIBITOR;

ALPHA ADRENERGIC RECEPTOR BLOCKING; ARTICLE; DISEASE ASSOCIATION; DIZZINESS; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; EJACULATION DISORDER; ERECTILE DYSFUNCTION; FAINTNESS; HOLMIUM LASER ENUCLEATION; HUMAN; LIBIDO DISORDER; LOW LEVEL LASER THERAPY; LOWER URINARY TRACT SYMPTOM; MEDICAL DEVICE; MONOTHERAPY; ORTHOSTATIC HYPOTENSION; PROSTATE HYPERTROPHY; PROSTATE PHOTOVAPORIZATION; PROSTATECTOMY; SEXUAL DYSFUNCTION; SEXUAL FUNCTION; SIDE EFFECT; SPERM; SUTURE; TESTOSTERONE BLOOD LEVEL; TRANSURETHRAL RESECTION; TREATMENT RESPONSE; URINARY TRACT DISEASE; UROLOGICAL PROCEDURE; LIBIDO; MALE; METHODOLOGY; REVIEW;

5-ALPHA REDUCTASE INHIBITORS; ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; ERECTILE DYSFUNCTION; HUMANS; LIBIDO; MALE; PHOSPHODIESTERASE 5 INHIBITORS; PROSTATECTOMY; PROSTATIC HYPERPLASIA;

EID: 84877119711     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-012-0278-5     Document Type: Article

References (54)

1. Berry SJ, Coffey DS, Walsh PC, et al. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132:474-9.
2. Price DT, Schwinn DA, Lomasney JW, et al. Identification, quantification, and localization of mRNA for three distinct alpha 1 adrenergic receptor subtypes in human prostate. J Urol. 1993;150:546-51.
3. •• McVary KT, Roehrborn CG, Avins AL, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol. 2011;185(5):1793-803. This AUA update provides an excellent review of the treatment of BPH.
4. Roehrborn CG. Efficacy of alpha-adrenergic receptor blockers in the treatment of male lower urinary tract symptoms. Rev Urol. 2009;11 Suppl 1:S1-8.
5. Roehrborn CG, Schwinn DA. Alpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia. J Urol. 2004;171(3):1029-35.
6. American Urological Association: AUA Guidelines on Management of Benign Prostatic Hyperplasia, 2003, revision 2006. Chapter 3. Available at http://www.auanet.org.
7. De la Rosette JJ, Kortmass BB, Rossi C. Long-term risk of re-treatment of patients using alpha-blockers for lower urinary tract symptoms. J Urol. 2002;167(4):1734-9.
8. Hellstrom WJ, Sikka SC. Effects of acute urinary retention with tamsulosin versus alfuzosin on ejaculatory function in normal volunteers. J Urol. 2006;176:1529-33.
9. Nagai A, Hara R, Yokoyama T. Ejaculatory dysfunction caused by the new alpha-blocker silodosin: a preliminary study to analyze human circulation using color Doppler ultrasonography. Int J Urol. 2008;15:915-8.
10. Hisasue S, Furuya R, Itoh N. Ejaculatory disorder caused by alpha 1 adrenoreceptor antagonists is not retrograde ejaculation by a loss of seminal emission. Int J Urol. 2006;13:1311-6.
11. Kobayashi K, Masumori N, Hisasue S. Inhibition of seminal emission is the main cause of anejaculation induced by a new highly selective alpha 1A blocker in normal volunteers. J Sex Med. 2008;5:2185-90.
12. Kirby RS, Roehrborn C, Hoyle P. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology. 2003;61:119-26.
13. Lepor H, Williford WO, Barry MJ. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl J Med. 1996;335:533-9.
14. Van Kerrebroeck P, Jardin A, Laval KU. Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfusozin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI Study Group. Eur Urol. 2000;37:306-13.
15. Van Kerrebroeck P, Jardin A, van Cangh P. Long-term safety and efficacy of a once-daily formulation of alfuzosin 10 mg in patients with symptomatic benign prostatic hyperplasia: open-label extension study. Eur Urol. 2002;41:54-60.
16. Elhilali M, Emberton M, Matzkin H. Long-term efficacy and safety of alfuzosing 10 mg once-daily: a 2-year experience in "real-life" practice. BJU Int. 2006;97:513-9.
17. Narayan P, Tewari A. A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. United States 93-01 Study Group. J Urol. 1998;160:1701-6.
18. Höfner K, Claes H, De Reijke TM. Tamsulosin 0.4 mg once daily: effect on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol. 1999;36:335-41.
19. Marks LS, Gittelman MC, Hill LA, et al. Rapid efficacy of highly selective alpha1A-adenoreceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: polled results of 2 phase 3 studies. J Urol. 2009;181:2634.
20. Marberger MJ. Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. PROWESS Study Group. Urology. 1998;51:677-86.
21. Roehrborn CG, Boyle P, Nickel JC. Efficacy and safety of dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology. 2002;60:431-41.
22. Roehrborn CG, Marks LS, Fenter T. Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia. Urology. 2004;63:709-15.
23. Dorsam J, Altwein J. 5 alpha-reductase inhibitor treatment of prostatic diseases: background and practical implications. Prostate Cancer Prostatic Dis. 2009;12(2):130-6.
24. Andersen JT, Ekman P, Wolf H. Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo controlled study. Urology. 1995;46:631.
25. McConnell JD, Bruskewitz R, Walsh P. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med. 1998;338(9):557-63.
26. Traish AM, Hassani J, Guay AT. Adverse side effects of 5α-reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients. J Sex Med. 2011;8(3):872-84.
27. McConnell JD, Roehrbon CG, Bautista OM. The long-term effect of doxasozin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349:2387.
28. •• Roehrborn CG, Siami P, Barkin J. The effects of combination therapy with duatsteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010;57:123. The CombAT study has had tremendous impact on the treatment of BPH with combination therapy. This article provides the 4 year data from this endeavor.
29. FDA: Postmarket Drug Safety Information for Patients and Providers, Cialis (tadalafil information). http://www.accessdata.fda.gov/scripts/cder/ drugsatfda/index.cfm?fuseaction=Search.Label-ApprovalHistory#apphist.
30. McVary KT, Roehrborn CG, Kaminetsky JC. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. Urology. 2007;177:1401-7.
31. Roehrborn CG, McVary KT, Wlion-Mboussa A. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol. 2008;180:1228-34.
32. Egerdie RB, Auerbach S, Roehrborn CG. Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study. J Sex Med. 2012;9:271-81.
33. Bechara A, Romano S, Casabé A. Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadalafil in the treatment of LUTS/BPH. Pilot study. J Sex Med. 2008;5:2170-8.
34. Liguori G, Trombetta C, De Girorgi G. Efficacy and safety of combined oral therapy with tadalafil and alfuzosin: an integrated approach to the management of patient with lower urinary tract symptoms and erectile dysfunction. Preliminary report. J Sex Med. 2009;6:544-52.
35. McVary KT, Monnig W, Camps Jr JL, et al. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol. 2007;177:1071.
36. Sairam K, Kulinskaya E, McNicholas TA. Sildenafil influences lower urinary tract symptoms. BJU Int. 2002;90:836.
37. Mulhall JP, Guhring P, Parker M. Assessment of the impact of sildenafil citrate on lower urinary tract symptoms in men with erectile dysfunction. J Sex Med. 2006;3:662.
38. Kaplan SA, Gonzalez RR, Te AE. Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur Urol. 2007;51(6):1717-23.
39. • Gacci M, Coronoa G, Salvi M. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol. 2012;61(5):994-1003. This review article provides relevant and recent data regarding the use of combination therapy involving PDE5 inhibitors in the treatment of men with BPH.
40. Stief CG, Porst H, Neuser D, et al. A randomized, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol. 2008;53(6):1236-44.
41. Kaplan SA, Roehrborn CG, Rovner ES. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder. JAMA. 2006;296:2319-28 (Published errata appear in JAMA 2007, 297:1195 and JAMA 2007, 298:1864).
42. •• Kaplan SA, Roehrborn CG, Abrams P. Antimuscarinics for the treatment of storage lower urinary tract symptoms in men: a systematic review. Int J Clin Pract. 2011;65(4):487-507. This review article provides an excellent review of antimuscarinics and provides data on their safe use in the treatment of men with BPH.
43. Muntener M, Aellig S, Kuettel R, et al. Sexual function after transurethral resection of the prostate (TURP): results of an independent prospective multicenter assessment of outcome. Eur Urol. 2007;52:510-5 (Published errata appear in the Eur Urol 2008, 53:456).
44. Poulakis V, Ferakis N, Witzsch U, et al. Erectile dysfunction after transurethral prostatectomy for lower urinary tract symptoms: results from a center with over 500 patients. Asian J Androl. 2006;8:69-74.
45. • Jaidane M, Arfa NB, Hmida W, et al. Effect of transurethral resection of the prostate on erectile function: a prospective comparative study. Int J Impot Res. 2010;22:146-51. This study used TURBT as a sham study for comparison with TURP and its effects on erectile function.
46. Arai Y, Aoki Y, Okubo K, et al. Impact of interventional therapy for benign prostatic hypertrophy on quality of life and sexual function: a prospective study. J Urol. 2000;164:1206-11.
47. Gacci M, Bartoletti R, Figlioli S, et al. Urinary symptoms, quality of life and sexual function in patients with benign prostatic hypertrophy before and after prostatectomy: a prospective study. BJU Int. 2003;91:196-200.
48. Kavoussi PK, Hermans MR. Maintenance of erectile function after photoselective vaporization of the prostate for obstructive benign prostatic hypertrophy. J Sex Med. 2008;5:2669-71.
49. Paick JS, Um JM, Kim SW, et al. Influence of high-power potassium-titanyl-phosphate photoselective vaporization of the prostate on erectile function: a short-term follow-up study. J Sex Med. 2007;4:1701-7.
50. Wilson LC, Gilling PJ, Williams A, et al. A randomized trial comparing holmium laser enucleation versus transurethral resection in the treatment of prostates larger than 40 grams: results at 2 years. Eur Urol. 2006;50:569-73.
51. Briganti A, Naspro R, Gallina A, et al. Impact on sexual function of holmium laser enucleation versus transurethral resection of the prostate: results of a prospective, 2 center, randomized trial. J Urol. 2006;175:1817-21.
52. Woo HH, Bolton DM, Laborde E, et al. Preservation of sexual function with the prostatic urethral lift: a novel treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Sex Med. 2012;9:568-75.
53. •• Chin PT, et al. Prostatic urethral lift: two-year results after treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 2011;5-11. This article provides 2 year data on the novel UroLift procedure.
54. NeoTract UroLift Website. http://www.neotract.com/ formedicalprofessionals-ous-q10095-c10049-UroLift-System.aspx.